Advertisment
Johnson & Johnson to present groundbreaking neuropsychiatric research at Psych Congress 2023, featuring advances in depression and schizophrenia treatments
Johnson & Johnson announced that 23 abstracts featuring new real-world and clinical trial data from across its neuropsychiatry portfolio and pipeline will be presented at the annual U.S. Psychiatric and Mental Health Congress (Psych Congress), taking place October 29 to November 2 in Boston, Massachusetts. Presentations include new data supporting the safety and efficacy of SPRAVATO® (esketamine) CIII nasal spray and the Company’s innovative portfolio of long-acting injectables (LAIs) for schizophrenia, as well as data highlighting the significant burden people living with major depressive disorder (MDD) and schizophrenia often face.
“For nearly seven decades, J&J has been at the forefront of driving scientific progress and innovation in neuroscience,” said Bill Martin, Ph.D., Global Neuroscience Therapeutic Area Head, Johnson & Johnson Innovative Medicine. “It is our responsibility and privilege to help advance research and understanding of MDD and schizophrenia so we can continue to deliver transformational therapies that address the greatest unmet patient needs.”
Key presentations include:
- New five-year, real-world safety data from nearly 35,000 adults treated with SPRAVATO®, building on more than a decade of research and reinforcing its well-studied, consistent safety profile (Poster 151).
- Novel insights into the clinical, humanistic and economic burden of anhedonia in adults with MDD (Poster 113).
- Results from an analysis of more than 30,000 adults with schizophrenia highlighting the link between symptom relapse and risk of death, which can occur 15‐20 years prematurely for adults living with schizophrenia compared to the general population due to many different causes.1 (Poster 42).
“Serious mental illness is one of the most complex health challenges of our time,” said Pearl Pugh, President, U.S. Neuroscience, Johnson & Johnson Innovative Medicine. “Understanding the patient experience is at the core of our mission to develop breakthrough solutions that can help improve care and make a difference in the lives of those living with challenging-to-treat mental illnesses.”
J&J will present the following posters at Psych Congress on October 31 at 1:30 – 3:30 p.m. ET and November 1 at 1:30 – 3:30 p.m. ET in the Exhibit Hall.
| Poster # | Title |
| Treatment-Resistant Depression | |
| 151 | Real-World Safety Profile of Esketamine Nasal Spray: An Analysis of the Risk Evaluation and Mitigation Strategy Program Approximately 5 Years After Approval in the United States |
| 112 | Efficacy and Safety of Esketamine Nasal Spray as Monotherapy in Adults with Treatment-Resistant Depression: A Randomized, Double-Blind, Placebo-Controlled Study |
| 102 | Weight and Metabolic Changes in Patients Treated with Esketamine Nasal Spray Versus Quetiapine Extended Release: A Post Hoc Subgroup Analysis of the ESCAPE-TRD Study |
| 200 | Clinical Effectiveness and Persistence on Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Overall and Among Transcranial Magnetic Stimulation-Naïve Subgroup |
| 202 | Response and Remission on Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Overall and Among TMS-Naive Subgroup |
| 203 | Comparison of Real-World Response and Remission Among Patients with Treatment-Resistant Depression Treated with Esketamine Nasal Spray or Antipsychotic Augmentation |
| 201 | Real-World Clinical Effectiveness of Esketamine Nasal Spray Based on the Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment-Resistant Depression in the United States |
| 148 | Trajectory of Response and Remission in Induction Nonresponders to Esketamine Nasal Spray: A Subgroup Analysis of the SUSTAIN-3 Study |
| Major Depressive Disorder | |
| 113 | Higher Anhedonia Is Associated with Poorer Clinical and Humanistic Outcomes Among U.S. Adults with Major Depressive Disorder |
| 124 | Seltorexant, Adjunctive to Antidepressants, in Adults with Major Depressive Disorder with Insomnia Symptoms: Results of a Double-Blind, Randomized, Placebo-Controlled Study |
| 206 | Adjunctive Treatment with Seltorexant Improved Patient-Reported Depressive Symptoms, Insomnia Symptoms, and Overall Health in Major Depressive Disorder with Insomnia |
| 59 | Pharmacokinetics and Safety of Seltorexant, Selective Orexin-2 Receptor Antagonist, in Healthy Elderly and Young Non-Asian, and Japanese Adult Participants |
| 145 | Major Depressive Disorder with Clinically Relevant Insomnia Symptoms: Healthcare Professional Assessment of Patient Impact and Clinical Management |
| 146 | Treating Insomnia Symptoms as Part of Major Depressive Disorder: A Cross-Sectional Survey on Patient Needs in the U.S. |
| 186 | How Do Patients with Depression and Their Providers Talk About Anhedonia? An Ethnographic Analysis of Healthcare Provider Conversations with Patients in the Clinical Setting |
| 16 | Burden of Prominent Anhedonia in Major Depressive Disorder Reflected in Polypharmacy, Healthcare Use, and Humanistic Outcomes |
| 64 | Clinical Burden and Treatment Satisfaction in a Real-World Survey of Patients Diagnosed with Major Depressive Disorder (MDD) With Prominent Anhedonia |
| 147 | Disease Burden Associated with Prominent Anhedonia in Patients with Major Depressive Disorder (MDD) from Adelphi Depression Disease Specific Program |
| 32 | Clinical Burden of Patients Diagnosed with Major Depressive Disorder with versus Without Prominent Anhedonia Using a Real-World Dataset in the United States |
| Schizophrenia | |
| 42 | Association of Relapse with All-Cause Mortality in 32,071 Adults with Stable Schizophrenia: A Longitudinal Commercial and Medicare Database Study |
| 39 | Characteristics and Antipsychotic Treatment Pathways of Patients with Schizophrenia Who Received Once-Every-6-Months Paliperidone Palmitate Within the First Two Years of Approval |
| 34 | Real-World Comparative Effectiveness of Long-Acting Injectable and Oral Antipsychotics Among U.S. Medicare Beneficiaries with Schizophrenia |
| 103 | Symptomatic and Functional Remission with Paliperidone Palmitate 3-Month and 6-Month Formulations in Adult Patients with Schizophrenia: A 3-Year Analysis |
